2Bauer SS, Dykeman JC, Augustin KM, et al. Prolonged engraftment and/or primary graft failure following allogenic stem cell transplant in patients treated with dasatinib [J]. Blood, 2006, 108(9):5259.
3Assouline S, Laneuville P, Gambacorti Passerini C. Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia[ J]. N Engl J Med, 2006, 354(24) : 2623-2624.
4Cortes J, O' Brien S, Jones D, et al, Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [J]. Blood, 2007, 110(1) : 30.
5Khan MA, Walling T, Cumpston A, et al. CMV colitis in a patient receiving dasatinib [ J ]. Blood, 2007, 110 (13) :4567.
6Garcia-Munoz R, Ruiz de Gaona E, Rodriguez-Otero P, et al. Reactivation of herpes virus-6 in a chronic myeloyd leukemia (CML) patient during treatment with dasatinib [ J ]. Haematologica, 2007, 92 ( Suppl 2) : 493.
7Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series[J]. Am J Respir Crit Care Med, 2007, 176 (8) : 814-818.
8Radaelli F, Bramanti S, Fantini NN, et al. Dasatinib related alveolar pneumonia responsive to corticosteroids [ J ]. Leuk Lymphoma, 2006, 47 ( 6 ) : 1180-1181.
9Fullmer A, Kantarjian H, Cortes J, et al. Dasatinib for the treat- ment of chronic myeloid leukemia IJl. Expert Rev Hematol, 2011, 4(3):253-260.
10NCCN clinical practice guidelines in oncology:chronic myeloge- nous leukemia [ S/OL ] .Version 2, 2013. http://www.nccn.org/pro- fessionals/physician-gls/f-guidelines.asp#cml.
